Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth

References

• Porter KR, McCarthy BJ, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12(6):520–527.
   PubMed Web of Science ®Google Scholar
• Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10(11):3728–3736.
   PubMed Web of Science ®Google Scholar
• Blanchette M, Tremblay L, Lepage M, et al. Impact of drug size on brain tumor and brain parenchyma delivery after a blood–brain barrier disruption. J Cereb Blood Flow Metab. 2014;34(5):820–826.
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol. 2015;17 (Suppl. 2):ii3–ii8.
   PubMedGoogle Scholar
• Ashby LS, Smith KA, Stea B. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol. 2016;14(1):225.
   PubMedGoogle Scholar
• Zhou Z, Singh R, Souweidane MM. Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment. Curr Neuropharmacol. 2016;15(1):116–128.
   Web of Science ®Google Scholar
• Casanova F, Carney PR, Sarntinoranont M. Effect of needle insertion speed on tissue injury, stress, and backflow distribution for convection-enhanced delivery in the rat brain. PLoS One. 2014;9(4):e94919.
   PubMed Web of Science ®Google Scholar
• Ramalho MJ, Coelho MAN, Pereira MC. Chapter 18 – nanocarriers for the delivery of temozolomide in the treatment of glioblastoma: a review. In: Grumezescu AM, editor. Design and development of new nanocarriers. Kidlington, Oxford: William Andrew Publishing; 2018. p. 687–722.
   Google Scholar
• Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
   PubMed Web of Science ®Google Scholar
• Cook RL, Householder KT, Chung EP, et al. A critical evaluation of drug delivery from ligand modified nanoparticles: confounding small molecule distribution and efficacy in the central nervous system. J Control Release. 2015;220:89–97.
   PubMed Web of Science ®Google Scholar
• Cui Y, Xu Q, Chow P-H, et al. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials. 2013;34(33):8511–8520.
   PubMed Web of Science ®Google Scholar
• Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:1–18.
   Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614–628.
   PubMed Web of Science ®Google Scholar
• Gao H, Xiong Y, Zhang S, et al. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm. 2014;11(3):1042–1052.
   PubMed Web of Science ®Google Scholar
• Schnell O, Krebs B, Wagner E, et al. Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008;18(3):378–386.
   PubMed Web of Science ®Google Scholar
• Miura Y, Takenaka T, Toh K, et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood–brain tumor barrier. ACS Nano. 2013;7(10):8583–8592.
   PubMed Web of Science ®Google Scholar
• Ha GE, Lee J, Kwak H, et al. The Ca(2+)-activated chloride channel anoctamin-2 mediates spike-frequency adaptation and regulates sensory transmission in thalamocortical neurons. Nat Commun. 2016;7(1):13791.
   PubMedGoogle Scholar
• Hoekman JD, Srivastava P, Ho RJ. Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J Pharm Sci. 2014;103(8):2231–2239.
   PubMed Web of Science ®Google Scholar
• Verrier S, Pallu S, Bareille R, et al. Function of linear and cyclic RGD-containing peptides in osteoprogenitor cells adhesion process. Biomaterials. 2002;23(2):585–596.
   PubMed Web of Science ®Google Scholar
• Frochot C, Di Stasio B, Vanderesse R, et al. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg Chem. 2007;35(3):205–220.
   PubMed Web of Science ®Google Scholar
• Fang Y, Jiang Y, Zou Y, et al. Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. Acta Biomater. 2017;50:396–406.
   PubMed Web of Science ®Google Scholar
• Liu H, Xie Y, Zhang Y, et al. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. Biomaterials. 2017;121:130–143.
   PubMed Web of Science ®Google Scholar
• Guo D, Shi C, Wang X, et al. Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: high loading capacity, increased stability, and improved anticancer efficacy. Biomaterials. 2017;141:161–175.
   PubMed Web of Science ®Google Scholar
• Siu WY, Yam CH, Poon RY. G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. FEBS Lett. 1999;461(3):299–305.
   PubMed Web of Science ®Google Scholar
• Beloor J, Choi CS, Nam HY, et al. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA. Biomaterials. 2012;33(5):1640–1650.
   PubMed Web of Science ®Google Scholar
• Bar-On O, Shapira M, Hershko DD. Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells. Anticancer Drugs. 2007;18(10):1113–1121.
   PubMed Web of Science ®Google Scholar
• Lorusso V, Giotta F, Bordonaro R, et al. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: a multicenter phase III study. Int J Oncol. 2014;45(5):2137–2142.
   PubMed Web of Science ®Google Scholar
• Nam L, Coll C, Erthal LCS, et al. Drug delivery nanosystems for the localized treatment of glioblastoma multiforme. Materials. 2018;11.
   Web of Science ®Google Scholar
• Byeon HJ, Thao Le Q, Lee S, et al. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. J Control Release. 2016;225:301–313.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab. 2012;32:1959–1972.
   PubMed Web of Science ®Google Scholar
• Lalatsa A, Schatzlein AG, Uchegbu IF. Strategies to deliver peptide drugs to the brain. Mol Pharm. 2014;11(4):1081–1093.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood–brain barrier: bottleneck in brain drug development. Neurotherapeutics. 2005;2(1):3–14.
   Google Scholar
• Alcalá-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target. 2010;18(3):179–190.
   PubMed Web of Science ®Google Scholar
• Belur LR, Temme A, Podetz-Pedersen KM, et al. Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum Gene Ther. 2017;28(7):576–587.
   PubMed Web of Science ®Google Scholar
• Ullah I, Chung K, Oh J, et al. Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia. Sci Rep. 2018;8(1):15041.
   PubMedGoogle Scholar
• Beloor J, Maes N, Ullah I, et al. Small interfering RNA-mediated control of virus replication in the CNS is therapeutic and enables natural immunity to West Nile virus. Cell Host Microbe. 2018;23(4):549–556 e543.
   PubMed Web of Science ®Google Scholar
• van Woensel M, Wauthoz N, Rosiere R, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers. 2013;5(4):1020–1048.
   PubMedGoogle Scholar
• Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654–1673.
   PubMed Web of Science ®Google Scholar
• Muntimadugu E, Dhommati R, Jain A, et al. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci. 2016;92:224–234.
   PubMed Web of Science ®Google Scholar
• Gao H. Perspectives on dual targeting delivery systems for brain tumors. J Neuroimmune Pharmacol. 2017;12(1):6–16.
   PubMed Web of Science ®Google Scholar
• Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6(4):268–286.
   PubMed Web of Science ®Google Scholar
• Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11–17.
   PubMed Web of Science ®Google Scholar
• Jang HJ, Jeong EJ, Lee KY. Carbon dioxide-generating PLG nanoparticles for controlled anti-cancer drug delivery. Pharm Res. 2018;35(3):59.
   PubMed Web of Science ®Google Scholar
• Xie Q, Thompson R, Hardy K, et al. A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med. 2008;6(1):77.
   PubMedGoogle Scholar
• Tan X, Kim G, Lee D, et al. A curcumin-loaded polymeric micelle as a carrier of a microRNA-21 antisense-oligonucleotide for enhanced anti-tumor effects in a glioblastoma animal model. Biomater Sci. 2018;6(2):407–417.
   PubMed Web of Science ®Google Scholar
• Jensen EC. Quantitative analysis of histological staining and fluorescence using Image. Anat Rec. 2013;296(3):378–381.
   Google Scholar
• Nazemiyeh E, Eskandani M, Sheikhloie H, et al. Formulation and physicochemical characterization of lycopene-loaded solid lipid nanoparticles. Adv Pharm Bull. 2016;6(2):235–241.
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, et al. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11(6):673–692.
   PubMed Web of Science ®Google Scholar
• Allison SD. Analysis of initial burst in PLGA microparticles. Expert Opin Drug Deliv. 2008;5(6):615–628.
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–223.
   PubMed Web of Science ®Google Scholar
• Basso J, Miranda A, Nunes S, et al. Hydrogel-based drug delivery nanosystems for the treatment of brain tumors. Gels. 2018;4(3):62.
   PubMed Web of Science ®Google Scholar
• Sun Y, Kang C, Liu F, et al. RGD peptide-based target drug delivery of doxorubicin nanomedicine. Drug Dev Res. 2017;78(6):283–291.
   PubMed Web of Science ®Google Scholar
• Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10(3):116.
   PubMed Web of Science ®Google Scholar
• Griffiths PC, Cattoz B, Ibrahim MS, et al. Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering. Eur J Pharm Biopharm. 2015;97:218–222.
   PubMed Web of Science ®Google Scholar
• Hoekman JD, Ho RJ. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg. 2011;113(3):641–651.
   PubMed Web of Science ®Google Scholar
• Ananda S, Nowak AK, Cher L, et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci. 2011;18(11):1444–1448.
   PubMed Web of Science ®Google Scholar
• Guntern R, Bouras C, Hof PR, et al. An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia. 1992;48(1):8–10.
   PubMedGoogle Scholar
• Voulgaris S, Partheni M, Karamouzis M, et al. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol. 2002;25(1):60–64.
   PubMed Web of Science ®Google Scholar
• Chu L, Wang A, Ni L, et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 2018;25(1):1634–1641.
   PubMed Web of Science ®Google Scholar
• Meng Q, Wang A, Hua H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. Int J Nanomedicine. 2018;13:705–718.
   PubMed Web of Science ®Google Scholar
• Jorgensen AS, Rasmussen AM, Andersen NKM, et al. Using cell nuclei features to detect colon cancer tissue in hematoxylin and eosin stained slides. Cytometry A. 2017;91:785–793.
   PubMedGoogle Scholar
• Anttila JE, Albert K, Wires ES, et al. Post-stroke intranasal (+)-naloxone delivery reduces microglial activation and improves behavioral recovery from ischemic injury. eNeuro. 2018;5(2).
   PubMed Web of Science ®Google Scholar
• Moffatt S, Cristiano R, Boyle R. Combined formulation of doxorubicin-Arg-Gly-Asp (RGD) and modified PEGylated PLGA-encapsulated nanocarrier improves anti-tumor activity. 2012 IEEE International Conference on Bioinformatics and Biomedicine Workshops; 2012. p. 903–909.
   Google Scholar